suPARnostic® is the only CE-IVD certified product range applied for clinical assessment of suPAR levels in human plasma and serum. 

Implementing suPARnostic® enables healthcare professionals to make fast clinical decisions based on prognostic evidence across diseases.

Help reduce crowding, stress, hospital costs and improve patient outcomes

Support your hospital’s initiative to reduce crowding, the stress of hospital staff, healthcare costs and improve patient outcomes by introducing the suPARnostic® biomarker test in your laboratory.

suPARnostic® TurbiLatex is validated for all major automated clinical chemistry analyzers and fits existing hospital workflows, enabling seamless implementation in clinical biochemistry departments and core laboratories.

How to interpret suPAR results

High quality results in minutes

A short turnaround time is key to optimizing clinical decision making and allowing timely patient care. suPARnostic® can improve the patient turnaround time and provide highquality prognostic results.

A suPAR level <4 ng/mL indicates a good prognosis and supports the decision to discharge the patient.

A suPAR level >6 ng/mL indicates the presence, progression, and severity of disease, organ damage, and mortality risk and supports further clinical attention.

Documented by 900+ publications

Here you can find a short summary of the research done on suPAR within 12 groups of disease areas and see how the suPAR level is affected within each type of disease.

“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”

MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen

NEW STUDY:
Early anakinra treatment of COVID-19 patients guided by suPAR saves lives

Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates